Business
Ocumetics Completes Virtual Site Initiation for First-In-Human Clinical Study of Accommodating Intraocular Lens
(TheNewswire) Calgary, Alberta – TheNewswire - June 26, 2025 - Ocumetics...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Completes Virtual Site Initiation for First-In-Human Clinical Study of Accommodating Intraocular Lens\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta –\n \n\n TheNewswire -\n \n\n June 26, 2025\n \n\n -\nOcumetics Technology Corp\n \n\n .\n \n\n (“Ocumetics” or the “Company”)\n(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced\nophthalmic technology, is pleased to announce the successful\ncompletion of a virtual site initiation visit at its clinical partner\nsite in Mexico City. This critical milestone confirms that the\ninvestigative site is fully prepared to conduct the upcoming\nfirst-in-human (FIH) clinical study of its revolutionary accommodating\nintraocular lens (the “Ocumetics Lens”), in accordance with\ninternational standards.\n \n\n\n\n Dean Burns, CEO of Ocumetics commented on the\nsignificance of the site inspection: “Conducting the clinical\npartner site initiation is a major step forward in bringing the\nOcumetics Lens to clinical reality. The site initiation occurred\nremotely and will be finalized when our team visits the site.\nSuccessful completion of this critical process confirms clinical\nreadiness to commence the study and to perform surgeries on our first\npatients. We couldn’t be more excited to proceed to validate the\nclinical environment for what will be a landmark moment in\nOcumetics’ history.”\n \n\n\n\n The site initiation assesses the site’s\ninfrastructure, clinical workflows, equipment compatibility, and staff\ntraining. This thorough evaluation ensures that all elements are in\nplace to support a safe, effective, and compliant clinical trial\nenvironment.\n \n\n\n\n Following a successful site initiation, the clinical\nsite is now preparing for final activation, enabling patient screening\nand selection to begin in preparation or FIH surgeries.\n \n\n\n\n About Ocumetics\n \n\n\n\n Ocumetics Technology Corp.\n \n\n (\n \n\n TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)\nis a Canadian research and product development company that\n \n\n is dedicated to developing advanced vision\ncorrection solutions that enhance the quality of life for patients.\n Through innovative research and development, Ocumetics aims to\ntransform the field of ophthalmology with...